Brief: Hillstream Enters Exclusive Option Agreement To Buy Clinical Stage Asset For Chronic Pruritis
11/09/2023 16:53
Sept 11 (Reuters) - Hillstream BioPharma Inc HILS.O :
* HILLSTREAM ENTERS INTO AN EXCLUSIVE OPTION AGREEMENT TO
ACQUIRE
A CLINICAL STAGE ASSET FOR CHRONIC PRURITIS
* HILLSTREAM BIOPHARMA INC - ANTICIPATE COMPLETION OF PHASE
1 &
PHASE 2 CLINICAL TRIALS IN CHRONIC PRURITIS OVER NEXT
APPROXIMATELY 12 MONTHS
* HILLSTREAM BIOPHARMA - INTENDS TO FIRST SEEK APPROVAL IN
ORPHAN
DISEASE FOR TREATMENT OF MODERATE TO SEVERE CHOLESTATIC PRURITIS
IN PATIENTS WITH PBC
Source text for Eikon: ID:nGNX18RDXG
Further company coverage: HILS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Canton Strategic Holdings
See all newsBrief: Canton Strategic Holdings, Inc. Expected To Be Included In Russell 3000® And Russell 2000®
Brief: Canton Strategic Authorizes Share Repurchase Program For Up To $50 Million In Common Stock
Canton Strategic Holdings Q1 net loss widens on higher expenses
Brief: Canton Strategic Holdings Reports Full Year 2025 Financial And Operational Results
Brief: Canton Strategic Holdings Inc - Enters Amended Sales Agreement With Clear Street And Virtu Americas - SEC Filing